Researchers at University of Cincinnati in the US have developed a DNA-based biomarker blood test to complement the prostate-specific antigen (PSA) test currently used to screen men for prostate cancer. The researchers conducted a meta-analysis of existing data related to DNA methylation in bodily fluids to evaluate a specific cancer biomarker known as GSTP1 as a screening tool for prostate cancer. The study included 1,635 prostate cancer cases and 573 controls, which were analysed for the current study, including whole blood, plasma, urine, ejaculates and other secretions. University of Cincinnati molecular epidemiologist Tianying Wu determined that GSTP1 was a significant biomarker for prostate cancer and could increase the specificity of prostate cancer diagnosis by up to 70 percent as compared to using the PSA test alone. “The PSA test is highly sensitive, but it cannot differentiate between prostate cancer and benign prostatic conditions such as benign prostatic hyperplasia, leading many men to have unnecessary biopsies,” Wu added.